Each filer's latest filing for 89532M101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
New Enterprise Associates 16, L.P.
13D/A
|
10.5% |
5/7/2026
Event 5/5/2026
|
||
| New Enterprise Associates 16, L.P. | 10.5% | |||
| NEA Partners 16, L.P. | 10.5% | |||
| Nea 16 GP, LLC | 10.5% | |||
| NEA 18 Venture Growth Equity, L.P. | 10.5% | |||
| NEA Partners 18 VGE, L.P. | 10.5% | |||
| Nea 18 Vge GP, LLC | 10.5% | |||
| Forest Baskett | 9.8% | |||
| Ali Behbahani | 10.5% | |||
| Carmen Chang | 10.5% | |||
| Anthony A. Florence, Jr. | 10.5% | |||
| Mohamad H. Makhzoumi | 10.5% | |||
| Scott D. Sandell | 10.5% | |||
| Paul Walker | 10.5% | |||
|
FMR LLC
13G/A
|
8.8% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 8.8% | |||
| Abigail P. Johnson | 8.8% | |||
| BlackRock, Inc. 13G/A | 6.9% |
10/27/2026
Event 9/30/2026
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
5.5% |
11/16/2026
Event 9/30/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 5.5% | |||
| FHMLSP, L.P. | 5.5% | |||
| FHMLSP, L.L.C. | 5.5% | |||
| Frazier Life Sciences X, L.P. | 0.3% | |||
| FHMLS X, L.P. | 0.3% | |||
| FHMLS X, L.L.C. | 0.3% | |||
| Frazier Life Sciences XI, L.P. | 0.9% | |||
| FHMLS XI, L.P. | 0.9% | |||
| FHMLS XI, L.L.C. | 0.9% | |||
| James N. Topper | 0.3% | |||
| Patrick J. Heron | 0.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Viking Global Investors LP
13G/A
|
4.2% |
11/14/2025
Event 9/30/2025
|
||
| Viking Global Investors LP | 4.2% | |||
| Viking Global Opportunities Parent GP LLC | 4.2% | |||
| Viking Global Opportunities GP LLC | 2.8% | |||
| Viking Global Opportunities Portfolio GP LLC | 2.8% | |||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.8% | |||
| Viking Global Opportunities Drawdown GP LLC | 1.4% | |||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 1.4% | |||
| Viking Global Opportunities Drawdown (Aggregator) LP | 1.4% | |||
| Halvorsen Ole Andreas | 4.2% | |||
| Ott David C. | 4.2% | |||
| Shabet Rose Sharon | 4.2% | |||
|
Rubric Capital Management LP
13G/A
|
2.9% |
2/13/2026
Event 12/31/2025
|
||
| Rubric Capital Management LP | 2.9% | |||
| David Rosen | 2.9% | |||
|
Venrock Healthcare Capital Partners II, L.P.
13G/A
|
1.4% |
2/14/2025
Event 12/31/2024
|
||
| Venrock Healthcare Capital Partners II, L.P. | 1.4% | |||
| VHCP Co-Investment Holdings II, LLC | 1.4% | |||
| VHCP Management II, LLC | 1.4% | |||
| Venrock Healthcare Capital Partners III, L.P. | 1.4% | |||
| VHCP Co-Investment Holdings III, LLC | 1.4% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 1.4% | |||
| VHCP Management III, LLC | 1.4% | |||
| VHCP Management EG, LLC | 1.4% | |||
| Nimish Shah | 1.4% | |||
| Bong Y Koh | 1.4% | |||
|
Rosalind Advisors, Inc.
13G/A
|
1.2% |
2/13/2025
Event 2/13/2025
|
||
| Rosalind Advisors, Inc. | 1.2% | |||
| Salamon Steven A J | 1.2% | |||
| Aharon Gil | 1.2% | |||
| Rosalind Master Fund L.P. | 1.2% | |||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 226 | 151 M | $2.17B |
| 2026 Q2 | 221 | 149 M | $2.76B |
| 2026 Q1 | 201 | 135 M | $1.61B |
| 2025 Q4 | 185 | 130 M | $1.63B |
| 2025 Q3 | 168 | 131 M | $1.19B |
| 2025 Q2 | 157 | 115 M | $627M |
| 2025 Q1 | 141 | 88.1 M | $554M |
| 2024 Q4 | 111 | 79.5 M | $330M |
| 2024 Q3 | 94 | 58.1 M | $194M |
| 2024 Q2 | 79 | 55.9 M | $167M |
| 2024 Q1 | 81 | 51.6 M | $178M |
| 2023 Q4 | 64 | 52.2 M | $70.0M |
| 2023 Q3 | 56 | 48.7 M | $106M |
| 2023 Q2 | 54 | 48.8 M | $117M |
| 2023 Q1 | 37 | 43.5 M | $80.4M |
| 2022 Q4 | 38 | 43.2 M | $83.3M |
| 2022 Q3 | 41 | 45.8 M | $70.5M |
| 2022 Q2 | 33 | 28.8 M | $80.8M |
| 2022 Q1 | 24 | 7.16 M | $32.9M |
| 2021 Q4 | 18 | 13.2 M | $10.3M |
| 2021 Q3 | 19 | 12.4 M | $17.4M |
| 2021 Q2 | 18 | 12.5 M | $28.1M |
| 2021 Q1 | 20 | 13.1 M | $35.6M |
| 2020 Q4 | 19 | 13.0 M | $31.7M |
| 2020 Q3 | 17 | 13.3 M | $53.5M |
| 2020 Q2 | 17 | 13.4 M | $88.0M |
| 2020 Q1 | 21 | 14.0 M | $45.9M |
| 2019 Q4 | 17 | 14.2 M | $53.2M |
| 2019 Q3 | 21 | 14.1 M | $63.5M |
| 2019 Q2 | 19 | 14.2 M | $106M |